帕比司他获批用于治疗多发性骨髓瘤。 - Suppr

Suppr

超能文献

Panobinostat approved for multiple myeloma.

出版信息

Cancer Discov. 2015 May;5(5):OF4. doi: 10.1158/2159-8290.CD-NB2015-040. Epub 2015 Mar 23.

DOI:10.1158/2159-8290.CD-NB2015-040

PMID:25802326

Abstract

摘要

相似文献

Panobinostat approved for multiple myeloma.

Cancer Discov. 2015 May;5(5):OF4. doi: 10.1158/2159-8290.CD-NB2015-040. Epub 2015 Mar 23.

Panobinostat (Farydak) for multiple myeloma.

Med Lett Drugs Ther. 2015 Aug 17;57(1475):e118-9.

Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.

Haematologica. 2015 Jul;100(7):e289-91. doi: 10.3324/haematol.2015.124164. Epub 2015 Mar 20.

Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.

Drugs Today (Barc). 2015 Aug;51(8):491-504. doi: 10.1358/dot.2015.51.8.2362311.

Panobinostat for the Treatment of Multiple Myeloma.

Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11.

Panobinostat: first global approval.

Drugs. 2015 Apr;75(6):695-704. doi: 10.1007/s40265-015-0388-8.

[Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].

Med Monatsschr Pharm. 2016 Apr;39(4):142-7.

Panobinostat for the management of multiple myeloma.

Future Oncol. 2017 Mar;13(6):477-488. doi: 10.2217/fon-2016-0329. Epub 2016 Oct 25.

Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.

Pharmacotherapy. 2015 Dec;35(12):1173-88. doi: 10.1002/phar.1671.

FDA approves new agent for multiple myeloma.

J Natl Cancer Inst. 2015 Jun 1;107(6):djv165. doi: 10.1093/jnci/djv165. Print 2015 Jun.

引用本文的文献

: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers.

Front Immunol. 2025 Jun 27;16:1591912. doi: 10.3389/fimmu.2025.1591912. eCollection 2025.

Mechanisms of HDACs in cancer development.

Front Immunol. 2025 Apr 7;16:1529239. doi: 10.3389/fimmu.2025.1529239. eCollection 2025.

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

BMC Cancer. 2024 Sep 19;24(1):1167. doi: 10.1186/s12885-024-12936-w.

Treatment of multiple myeloma: What is the impact on T-cell function?

Ther Adv Hematol. 2024 May 7;15:20406207241245194. doi: 10.1177/20406207241245194. eCollection 2024.

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.

Nat Cancer. 2023 May;4(5):754-773. doi: 10.1038/s43018-023-00550-x. Epub 2023 May 26.

Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer.

Oncoimmunology. 2022 Feb 22;11(1):2042065. doi: 10.1080/2162402X.2022.2042065. eCollection 2022.

Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.

Clin Epigenetics. 2021 May 17;13(1):113. doi: 10.1186/s13148-021-01098-2.

Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.

Int J Cancer. 2020 Nov 15;147(10):2811-2823. doi: 10.1002/ijc.33046. Epub 2020 Jun 29.

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.

Cancer Sci. 2020 Feb;111(2):561-570. doi: 10.1111/cas.14260. Epub 2020 Jan 6.

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.

Ther Adv Chronic Dis. 2019 Jul 18;10:2040622319862697. doi: 10.1177/2040622319862697. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验